Recent Updates
Recently added Catalysts
CGON Positive Sentiment

CG Oncology to Present at Upcoming Investor Conferences in September

Key Takeaway: CG Oncology, Inc. announced that its CEO, Arthur Kuan, will present at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in September 2026. The presentations will take place on September 9 and September 14, respectively. Interested parties can access the live audio webcasts from the company's website, with replays available afterward.

Market Sentiment Analysis

POSITIVE FACTORS

  • CEO Arthur Kuan will present at major healthcare conferences.
  • Participation in investor conferences indicates strong company visibility.
  • Focus on innovative therapies for bladder cancer shows commitment to patient care.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:

Cantor Fitzgerald Global Healthcare Conference Presentation Time: Wednesday, September 9, 2026 at 8:00am ET

Morgan Stanley Global Healthcare Conference Presentation Time: Monday, September 14, 2026 at 4:50pm ET

Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replays will be available shortly after the conclusion of the live presentations and archived for approximately 90 days.
About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Contacts: Media Sarah Connors Vice President, Communications and Patient Advocacy, CG Oncology sarah.connors@cgoncology.com

Frequently Asked Questions

When is CG Oncology's presentation at the Cantor Fitzgerald Conference?

CG Oncology will present at the Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, at 8:00am ET.

How can I access the conference presentations?

Live audio webcasts of the presentations can be accessed from the Investor Relations section of CG Oncology's website.

What is CG Oncology focused on developing?

CG Oncology is focused on developing a bladder-sparing therapeutic for bladder cancer patients.

Who is the CEO of CG Oncology?

Arthur Kuan is the Chairman, President, and CEO of CG Oncology.

Last updated: Sep 2, 2026